Hepatitis Forums

Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on November 30, 2017, 10:27:40 am

Title: Experimental NASH Drug Reduces Liver Fat
Post by: Hep Editors on November 30, 2017, 10:27:40 am
GS-0976, an acetyl-CoA carboxylase inhibitor, reduced liver fat accumulation and led to small improvements in fibrosis markers in people with non-alcoholic steatohepatitis (NASH), according to a report presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting, held last week in Washington, DC.

Nearly half of study participants who took the highest dose of GS-0976 saw at least a 30 percent reduction in liver steatosis (fat accumulation), according to magnetic resonance imaging (MRI). However, a rise in triglycerides could be a concern, requiring longer-term follow-up.

Read more...
https://www.hepmag.com/article/experimental-nash-drug-GS0976-reduces-liver-fat